drug
argatroban
Marketedupdated 6mo agoby Mylan Institutional Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying argatroban
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 26, 2027
313 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Sep 26, 2027formulationUS 7589106313d
- Sep 26, 2027formulationUS 7687516313d
News(1)
- Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate MatterFOR IMMEDIATE RELEASE - ROCHESTER, MI– October 13, 2026 – Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducte…fda_medwatch · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that